Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen, Prepping for IPO, Says Revenues Grew 200 Percent Since 2004

NEW YORK (GenomeWeb News) – NimbleGen, which late last week said it has filed for an initial public offering with the Securities and Exchange Commission, said revenues increased 200 percent and that it has accumulated $20 million in net losses over the past three years.
In the SEC document, the company said revenues increased from $4.5 million in 2004 to $13.5 million in 2006 on increasing sales. The firm also said grant revenue declined during that period.
NimbleGen said it recorded $7 million in net losses in 2006, $5 million in 2005, and $8 million in 2004.
The company said R&D spending is focused on new microarrray applications, new software applications, reagents and kits for use with microarrays, and developing Maskless Array Synthesizer, or MAS, systems.
NimbleGen said it plans to use the proceeds from the IPO to expand the commercial and marketing infrastructure for its microarray products and services; increase R&D spending on next-generation manufacturing equipment; increase production capacity, and pay for general expenses.
The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.